This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- XmAb 2513
- DrugBank Accession Number
- DB06324
- Background
XmAb 2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. It has been investigated for the treatment of hodgkin’s lymphoma.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Monoclonal antibody (mAb) - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Not Available
- External IDs
- XmAb 2513
- XMAB-2513
- XmAb2513
Pharmacology
- Indication
Investigated for use/treatment in lymphoma (unspecified) and lymphoma (non-hodgkin's).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
XmAb™2513 is a humanized monoclonal antibody that targets the antigen CD30, a molecule expressed on the surface of a number of tumor cell types. XmAb™2513 has an XmAb™ Fc domain which increases its cytotoxic potency. XmAb™2513 recruits primary human immune cells to kill tumor cells in vitro models and is active in blocking tumor growth in rodent models. [Xencor Website]
Target Actions Organism UTumor necrosis factor receptor superfamily member 8 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbciximab The risk or severity of adverse effects can be increased when Abciximab is combined with XmAb 2513. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with XmAb 2513. Aducanumab The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Aducanumab. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with XmAb 2513. Alirocumab The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Alirocumab. Amivantamab The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Amivantamab. Anifrolumab The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Anifrolumab. Ansuvimab The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Ansuvimab. Anthrax immune globulin human The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Anthrax immune globulin human. Antilymphocyte immunoglobulin (horse) The risk or severity of adverse effects can be increased when XmAb 2513 is combined with Antilymphocyte immunoglobulin (horse). 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 33VWC847G8
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Anaplastic Large Cell Lymphoma / Hodgkin's Lymphoma 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Tumor necrosis factor-activated receptor activity
- Specific Function
- Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B.
- Gene Name
- TNFRSF8
- Uniprot ID
- P28908
- Uniprot Name
- Tumor necrosis factor receptor superfamily member 8
- Molecular Weight
- 63746.47 Da
Drug created at March 19, 2008 16:24 / Updated at November 29, 2022 09:06